ProKidney Corp.

PROK | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.77

-$0.14 (-7.33%)

At close: Sep 21, 2026, 4:00 PM ET

$1.77

$0 (0.00%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-7.33%

(1D)

Rating

Updated: Aug 12, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $596.85M

1D Range

1.72 1.88

52W Range

1.30 3.48

Valuation (TTM)

PE -3.11

PB 2.68

EV/EBITDA -2.60

Valuation (NTM)

Forward PE N/A

Forward PEG -3.73

Price Target $4.67

Cash Flow

FCF Yield -26.8%

SBC Adj. FCF Yield -29.5%

SBC Impact -10.2%

Margins

Gross Margin -252.6%

Operating Margin -21664.5%

FCF Margin -19527.4%

Growth (CAGR)

Revenue 3Y | 5Y 91.2% | 80.4%

Dil EPS 3Y | 5Y 2.6% | 9.5%

FCF 3Y | 5Y -2.1% | -11.2%

Returns

ROA -34.8%

ROE 8.8%

ROIC -68.1%

Financial Health

Net Cash

$179.17M

Current Ratio 8.36

Interest Coverage -9,327.16

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Ther...

Sector Healthcare

Industry Biotechnology

Employees 231

IPO Date Jun 29, 2021

Website www.prokidney.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+182.49%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞